• Home
  • About Us
  • Technology
  • Pipeline
  • Team
  • Partnerships
  • Media
  • Publications
  • Contact Us
HDT Bio

HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative

Sep 17, 2024 | Press Releases, Uncategorized

HDT bio’s Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17, 2024 /PRNewswire/ — HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies,...

Recent Posts

  • Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines
  • HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative
  • HDT Bio Publishes Peer-Reviewed Article Describing the Development of an RNA Vaccine to Prevent Infection and Disease Caused by Enterovirus D68
  • A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models – Science Translational Medicine
  • Bioprocess Online Live: Capital, Manufacturing Market Acceptance Of Therapeutic Cancer Vaccines

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow